Under a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, caution the WHO as it issues its initial recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging more widespread and fairer access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidelines affirms that obesity is a long-term condition that can be addressed with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to universal availability to the injections that can help people shift considerable body mass, notes the body.
Skinny Jab Shortage
Despite the present most optimistic scenario, the production of such drugs could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation calls on governments and firms to widen availability, through approaches such as voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs mimick a biological compound to delay gastric emptying, suppress the appetite and increase the sense of being full so individuals reduce food intake.
People usually begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence suggests people may see weight return within a year of stopping the treatment, when their normal food cravings resume.
To be above a healthy weight raises your risk for contracting diseases, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity impacts individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.
